These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 17396118)
21. [Evaluation of serum iron as a predictor of a hemoglobin response to injectable iron treatment in chronic hemodialysis patients]. Grèze C; Garrouste C; Pereira B; Hadj-Abdelkader M; Heng AÉ; Aniort J Nephrol Ther; 2022 Dec; 18(7):634-642. PubMed ID: 36216731 [TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of iron indices in hemodialysis patients receiving epoetin. Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA; Kidney Int; 2001 Jul; 60(1):300-8. PubMed ID: 11422765 [TBL] [Abstract][Full Text] [Related]
23. Monitoring iron status in end-stage renal disease patients on hemodialysis. Rafi A; Karkar A; Abdelrahman M Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895 [TBL] [Abstract][Full Text] [Related]
24. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. Pollak VE; Lorch JA; Shukla R; Satwah S BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700 [TBL] [Abstract][Full Text] [Related]
25. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients. Nguyen TV Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125 [TBL] [Abstract][Full Text] [Related]
26. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose. Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327 [TBL] [Abstract][Full Text] [Related]
27. Usefulness of Reticulocyte Hemoglobin Equivalent in Management of Regular Hemodialysis Patients with Iron Deficiency Anemia. Dalimunthe NN; Lubis AR Rom J Intern Med; 2016; 54(1):31-6. PubMed ID: 27141568 [TBL] [Abstract][Full Text] [Related]
28. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875 [TBL] [Abstract][Full Text] [Related]
30. A comprehensive vision for intravenous iron therapy. Coyne DW Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257 [TBL] [Abstract][Full Text] [Related]
31. Influence of intravenous iron therapy on novel markers of iron deficiency. Chinnappa S; Bhandari S Int J Artif Organs; 2010 May; 33(5):297-301. PubMed ID: 20593351 [TBL] [Abstract][Full Text] [Related]
32. Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency. Brătescu LO; Bârsan L; Gârneaţă L; Stanciu A; Lipan M; Stancu SH; Mircescu G Int Urol Nephrol; 2014 May; 46(5):1005-12. PubMed ID: 24800994 [TBL] [Abstract][Full Text] [Related]
33. National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients. Owen WF; Szczech L; Johnson C; Frankenfield D Am J Kidney Dis; 1999 Oct; 34(4 Suppl 2):S5-S11. PubMed ID: 10516369 [TBL] [Abstract][Full Text] [Related]
34. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Fishbane S; Shapiro W; Dutka P; Valenzuela OF; Faubert J Kidney Int; 2001 Dec; 60(6):2406-11. PubMed ID: 11737617 [TBL] [Abstract][Full Text] [Related]
35. Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis. Drozdz M; Weigert A; Silva F; Frazão J; Alsuwaida A; Krishnan M; Kleophas W; Brzosko S; Johansson FK; Jacobson SH BMC Nephrol; 2019 Jan; 20(1):5. PubMed ID: 30616548 [TBL] [Abstract][Full Text] [Related]
36. The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis . Umanath K; Greco B; Jalal DI; McFadden M; Sika M; Koury MJ; Niecestro R; Hunsicker LG; Greene T; Lewis JB; Dwyer JP Clin Nephrol; 2017 Mar; 87 (2017)(3):124-133. PubMed ID: 28128726 [TBL] [Abstract][Full Text] [Related]
37. Refining the approach to IV iron use in hemodialysis patients: a post-DRIVE analysis. Sharma A; Vanderhalt K; Ryan KJ; Sclafani J Nephrol News Issues; 2010 Apr; 24(4):22-6, 29-35. PubMed ID: 20458992 [TBL] [Abstract][Full Text] [Related]
38. Association of Anemia and Iron Parameters With Mortality Among Patients Undergoing Prevalent Hemodialysis in Taiwan: The AIM - HD Study. Kuo KL; Hung SC; Tseng WC; Tsai MT; Liu JS; Lin MH; Hsu CC; Tarng DC; J Am Heart Assoc; 2018 Aug; 7(15):e009206. PubMed ID: 30371224 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Oral Supplementation with Liposomal Iron in Non-Dialysis Chronic Kidney Disease Patients with Iron Deficiency. Cesarano D; Borrelli S; Campilongo G; D'Ambra A; Papadia F; Garofalo C; De Marco A; Marzano F; Ruotolo C; Gesualdo L; Cirillo P; Minutolo R Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732502 [TBL] [Abstract][Full Text] [Related]
40. Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations. Schatz U; Arneth B; Siegert G; Siegels D; Fischer S; Julius U; Bornstein SR Atheroscler Suppl; 2013 Jan; 14(1):115-22. PubMed ID: 23357152 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]